Abstract
A polypeptide containing an albumin-binding domain (ABD), an amino acid sequence linker, and glucagon-like peptide-1 (GLP-1), a potential antidiabetic agent, is designed to slowly release GLP-1 through sequential cleavage by native plasma proteases (see picture). The half-life of the polypeptide in the bloodstream is extended by its association with human serum albumin (HSA).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
